Germany pushes to cover weight-loss injections under public health insurance

A push is underway in Germany to make weight-loss injections more accessible for those in need. The Petitions Committee has urged the Federal Ministry of Health (BMG) to review funding for these treatments when medically justified. Currently, such drugs are labelled as 'lifestyle medications' and excluded from statutory health insurance coverage.

Obesity remains a widespread issue in the country, affecting one in six children, two-thirds of men, and half of women. While standard treatments exist, the committee's recommendation targets severe cases where other methods have failed.

Lower Saxony's Health Minister, Dr. Andreas Philippi, backs the proposal for Type 2 diabetics, suggesting prescriptions could cover costs. For broader obesity cases, he proposes a two-step process similar to gastric bypass approvals—requiring proof of long-term weight-loss struggles.

The BMG is closely tracking research on new weight-loss drugs, particularly GLP-1 agonists. However, the Petitions Committee stresses that any reclassification depends on further evidence of safety and long-term benefits.

If approved, the change would mark a shift in how obesity treatments are funded. Patients with severe conditions or diabetes could gain better access to these medications. The final decision rests on ongoing studies and regulatory reviews.